Managing pregnancy in chronic myeloid leukaemia

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 167-176

  Palani, Renuka ^a   Milojkovic, Dragana ^a   Apperley, Jane F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Fertility; Pregnancy; Tyrosine kinase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BOSUTINIB; CYTOTOXIC AGENT; DASATINIB; HYDROXYUREA; IMATINIB; LOW MOLECULAR WEIGHT HEPARIN; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TERATOGENIC AGENT;

AREA UNDER THE CURVE; BREAST FEEDING; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CRYOPRESERVATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY PLANNING; FEMALE INFERTILITY; FERTILITY PRESERVATION; FERTILIZATION; FETUS DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKAPHERESIS; NONHUMAN; OOCYTE RETRIEVAL; ORGAN PRESERVATION; PATIENT CARE; PHYSICIAN; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CONTRAINDICATIONS; DRUG MONITORING; ENZYMOLOGY; EVIDENCE BASED MEDICINE; FEMALE; LACTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; PERSONALIZED MEDICINE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FEMALE; FERTILITY PRESERVATION; HUMANS; INDIVIDUALIZED MEDICINE; LACTATION; LEUKAPHERESIS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PATIENT EDUCATION AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TERATOGENS;

EID: 84925932859     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2317-z     Document Type: Review

References (49)

1. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035
2. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515–522
3. (2014) Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation
4. (2014) Sprycel (dasatinib): prescribing information. Princeton, NJ: Bristol-Myers Squibb Company
5. (2014) Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation
6. He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ (2008) Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Dispos 26(12):2564–2570
7. (2013) Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc
8. (2014) Inclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, Inc
9. Ault P, Kantarjian H, O’Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204–1208
10. Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40(2suppl3):21–25
11. Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G (2008) Male patients with chronic myeloid leukemia treated with Imatinib involved in healthy pregnancies: report of five cases. Leuk Res 32(3):519–520
12. Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137(4):374–375
13. Iqbal J, Ali Z, Khan AU, Aziz Z (2014) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma
14. Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH (2013) Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res 37(10):1216–1221
15. Cortes J, O’Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H (2008) Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112(11). Abstract 3230: Poster presented at: the 50th American Society of Hematology (ASH) Annual Meeting; December 6–9, 2008; San Francisco, USA
16. Gentile M, Guido M, Lucia E, Vigna E, Mazzone C, Recchia AG, Morabito F (2014) Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma 55(3):709–710
17. Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A (2011) Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 283(1):133–134
18. Abrusezze E, Trawinska MM, Perrotti AP, De Fabritiis P (2014) Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6(1):e2014028
19. Pye SM, Cortes J, Ault P, Hatfied A, Kantarjian H, Pilot R, Rosti G, Apperly J (2008) The effects of Imatinib on pregnancy outcome. Blood 111:5505–5508
20. Laferla JJ (1986) Spontaneous abortion. Clin Obstet Gynaecol 13:105–114
21. Soriano P (1997) The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124:2691–2700
22. Bleyl SB, Moshrefi A, Shaw GM, Saijoh Y, Schoenwolf GC, Pennacchio LA, Slavotinek AM (2007) Candidate genes for congenital diaphragmatic hernia from animal models: sequencing of FOG2 and PDGFR alpha reveals rare variants in diaphragmatic hernia patients. Eur J Hum Genet 15:950–958
23. Sun T, Jayatilake D, Afink GB, Ataliotis P, Nistér M, Richardson WD, Smith HK (2000) A human YAC transgene rescues craniofacial and neural tube development in PDGFR alpha knockout mice and uncovers a role for PDGFR alpha in prenatal lung growth. Development 127:4519–4529
24. Bayraktar S, Morency B, Escalon MP (2010) Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports Online Publication
25. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Lacer PE, Bendit I (2010) Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252
26. Kroll T, Ames MB, Pruett JA, Fenske TS (2010) Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 51(9):1751–1753
27. Dine G, Levert M, Rehn Y, Ali AN, Brahimi S, Gaillard B, Bocq I, Fumagalli G (2013) Two successful successive pregnancies in a woman with CML treated with dasatinib and temporary peg-interferon. J US-China Med Sci 10(5–6):128–133
28. Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V (2012) A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs 23(7):754–757
29. Conchon M, Sanabani SS, Bendit I (2009) Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 42(2)
30. Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE (2010) French Intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer 97(8):997–1009
31. Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukaemia: implications for intermittent imatinib therapy. Leuk Lymphoma 50(6):944–951
32. Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D (2010) Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014–1016
33. Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167–169
34. Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, Al-Hassan A (2002) Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-a in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 69:115–118
35. Hiratsuka M, Minakami H, Koshizuka S, Sato I (2000) Administration of interferon-a during pregnancy: effect on fetus. J Perinat Med 28:372–376
36. Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha 2a and no treatment. A comprehensive analysis of the literature. Acta Hematol 107:158–169
37. Regierer AC, Schulz CO, Kuehnhardt D, Flath B, Possinger K (2006) Interferon a—therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 81:149–156
38. Al Bahar S, Pandita R, Nath SV (2004) Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynecol Obstet 85:281–282
39. Kuroiwa M, Gondo H, Ashida K, Kamimura T, Miyamoto T, Niho Y, Tsukimori K, Nakano H, Ohga S (1998) Interferon alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 59:101–102
40. Thauvin Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S, Nivelon-Chevallier A (2001) Exposure to hydroxyurea during pregnancy: a case series. Leukemia 15:1309–1311
41. Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M (2002) Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202–1203
42. Russel MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. J Perinatol 27:241–243
43. Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A (2009) Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280(2):169–175, 2008
44. (2006) Bristol-Myers Squibb Canada. HYDREA® product monograph. Montreal, Quebec
45. Kumar AR, Hale TW, Mock RE (2000) Transfer of interferon alfa into human breast milk. J Hum Lact 16(3):226–228
46. Lichtman MLJ (2001) 6th ed. Vol. 1047. New York, NY: McGraw-Hill. Acute myelogenous leukemia. Williams Hematology
47. Sheehy WT (1958) An evaluation of the effect of pregnancy on chronic granulocytic leukaemia. Am J Obstet Gynecol 75:788
48. Ali R, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in patient with CML and management of CML with leukapheresis during pregnancy. Jpn J Clin Oncol 34:215–217
49. Klaasen R, de-Jong P, Wijermans PW (2007) Successful management of chronic myeloid leukemia with leucapheresis during a twin pregnancy. Neth J Med 65:147–149